Streamlining systems to respond to COVID-19

When the coronavirus pandemic broke out, Paul Aliu knew that he would have to act fast. His team at Novartis soon received a deluge of requests from physicians around the world. Doctors asked to access the company’s medicines more than 1 000 times during the first two months of the crisis to help patients with COVID-19 disease.

…
/by

World Sickle Cell Day 2020

As the world grapples with the COVID-19 pandemic, we need to continue our efforts to support vulnerable populations, who may be more at risk, such as people with sickle cell disease (SCD).

Sickle cell disease is a hereditary and life-threatening condition that causes ongoing vascular damage and repeated injury to the blood vessels and organs, including the heart and lungs. This lifelong illness often takes an extreme emotional, physical, and financial toll on patients and their families.

A holistic …

/by

Novartis expands Africa Sickle Cell Disease program to Uganda and Tanzania

  • New collaborations aim to reduce the burden of sickle cell disease (SCD) in East Africa and improve access to high quality care
     
  • Program continues progress in Ghana with more than 2000 patients being treated with hydroxyurea in 11 treatment centers across the country
     
  • Novartis plans to roll the program out to a total of 10 African countries by 2022
     
  • Approximately 1 000 children in Africa are born with SCD every day and more than half will die before they reach the age of five1

    • …

/by